• slidebg1

    Collaborate

    CRISPR is an early-stage company
    created to translate breakthrough
    gene-editing technology into transformative
    medicines for serious human diseases.
    Abingworth is helping CRISPR to select
    its first therapeutic indications
    and build its team.

  • slidebg1

    Innovate

    Nasdaq-listed Paratek is developing novel
    antibiotics to tackle community-acquired
    infections. Abingworth helped recruit the
    team and co-led the investment.

  • slidebg1

    Create

    Pixium is restoring vision and autonomy
    to the blind. Abingworth has supported
    the French company from its inception to its
    IPO on Euronext.

  • slidebg1

    Collaborate

    Avillion is a clinical co-development
    company providing funding and
    operational expertise to accelerate
    the development of late stage
    therapeutics. Abingworth created and
    incubated the UK-based company.

  • slidebg1

    Innovate

    Abingworth is working with eFFECTOR to
    develop a novel class of small molecule drugs
    that selectively regulate translational
    control of gene expression. The clinical stage
    company has an initial emphasis on cancer,
    including immuno-oncology.

  • slidebg1

    Create

    Personalis provides researchers and
    clinicians with advanced genome sequencing
    and interpretation services for inherited
    genetic diseases and cancer. Abingworth
    led the series A financing.

Latest News
5 Dec 2016
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia   Read More
5 Dec 2016
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease  Read More
7 Nov 2016
MEDIAN Technologies announces a reserved share capital increase to FURUI of €19.6 Million at a €13 per share price  Read More
 

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Collaborate
CRISPR is an early-stage company created to translate breakthrough gene-editing technology into transformative medicines for serious human diseases. Abingworth is helping CRISPR to select its first therapeutic indications and build its team.
Innovate
Nasdaq-listed Paratek is developing novel antibiotics to tackle community-acquired infections. Abingworth helped recruit the team and led the investment.
Create
Pixium is restoring vision and autonomy to the blind. Abingworth has supported the French company from its inception to its IPO on Euronext.
Collaborate
Avillion is a clinical co-development company providing funding and operational expertise to accelerate the development of late stage therapeutics. Abingworth created and incubated the UK-based company.
Innovate
Abingworth is working with eFFECTOR to develop a novel class of small molecule drugs that selectively regulate translational control of gene expression. The clinical stage company has an initial emphasis on cancer, including immuno-oncology.
Create
Personalis provides researchers and clinicians with advanced genome sequencing and interpretation services for inherited genetic diseases and cancer. Abingworth led the series A financing.
 
Latest News
5 Dec 2016
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia   Read More
5 Dec 2016
Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease  Read More
7 Nov 2016
MEDIAN Technologies announces a reserved share capital increase to FURUI of €19.6 Million at a €13 per share price  Read More
Copyright Abingworth 2016